Lee P.K. Jarosek S.L. Virnig B.A. et al.

Trends in the incidence and treatment of parathyroid cancer in the United States.

Cancer. 109: 1736-1741Sadler C. Gow K.W. Beierle E.A. et al.

Parathyroid carcinoma in more than 1,000 patients: A population-level analysis.

Surgery. 156 (): 1622-1629Kong S.H. Kim J.H. Park M.Y. et al.

Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort.

J Cancer Res Clin Oncol. 147: 3091-3097Lo W.M. Good M.L. Nilubol N. et al.

Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma.

Ann Surg Oncol. 25: 2535-2540Asare E.A. Sturgeon C. Winchester D.J. et al.

Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the national cancer data base (NCDB).

Ann Of Surg Oncol. 22: 3990-3995Bilezikian J.P. Khan A.A. Potts Jr., J.T.

Third International Workshop on the Management of Asymptomatic Primary H. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

J Of Clin Endocrinol And Metab. 94: 335-339

Parathyroid Carcinoma: Diagnosis and Clinical Implications.

Turk Patoloji Derg. 31: 80-97Asare E.A. Silva-Figueroa A. Hess K.R. et al.

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center.

Ann Of Surg Oncol. 26: 3593-3599

Contemporary Evaluation and Management of Parathyroid Carcinoma.

JCO Oncol Pract. ()https://doi.org/10.1200/JOP.19.00540Silva-Figueroa A. Perrier N.D.

Diagnosis and Surgical Management of Parathyroid Carcinoma.

in: Shifrin A.L. Raffaelli M. Randolph G.W. Endocrine surgery comprehensive board exam guide. Springer International Publishing, : 379-403Erickson L.A. Mete O. Juhlin C.C. et al.

Overview of the 2022 WHO Classification of Parathyroid Tumors.

Endocr Pathol. 33: 64-89Salcuni A.S. Cetani F. Guarnieri V. et al.

Parathyroid carcinoma.

Best Pract Res Clin Endocrinol Metab. 32: 877-889Sandelin K. Auer G. Bondeson L. et al.

Prognostic factors in parathyroid cancer: a review of 95 cases.

World J Surg. 16: 724-731

Clinical review 122: Parathyroid carcinoma.

J Of Clin Endocrinol And Metab. 86: 485-493Wiseman S.M. Rigual N.R. Hicks Jr., W.L. et al.

Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes.

Ear Nose Throat J. 83: 491-494

Clinical presentation, staging and long-term evolution of parathyroid cancer.

Ann Surg Oncol. 17: 2156-2174Harari A. Waring A. Fernandez-Ranvier G. et al.

Parathyroid carcinoma: a 43-year outcome and survival analysis.

J Of Clin Endocrinol And Metab. 96: 3679-3686Al-Kurd A. Mekel M. Mazeh H.

Parathyroid carcinoma.

Surg Oncol. 23: 107-114Christakis I. Silva A.M. Kwatampora L.J. et al.

Oncologic progress for the treatment of parathyroid carcinoma is needed.

J Surg Oncol. https://doi.org/10.1002/jso.24407Amin M.B. Greene F.L. Edge S.B. et al.

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

CA Cancer J Clin. 67: 93-99

Parathyroid carcinoma: a diagnostic and therapeutic challenge.

Cancer. 86: 378-380Schulte K.M. Gill A.J. Barczynski M. et al.

Classification of parathyroid cancer.

Ann Surg Oncol. 19: 2620-2628

Current and future treatments for parathyroid carcinoma.

Int J Endocr Oncol. https://doi.org/10.2217/ije-2017-0011Amin M.B. Edge S.B. Green F.L. et al.

AJCC cancer staging manual.

8th edition. Springer, Cham

Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.

Clin Endocrinol. 92: 295-302Leonard-Murali S. Ivanics T. Kwon D.S. et al.

Local resection versus radical surgery for parathyroid carcinoma: a national cancer database analysis.

Eur J Of Surg Oncol. 47: 2768-2773Qian B. Qian Y. Hu L. et al.

Prognostic Analysis for Patients With Parathyroid Carcinoma: A Population-Based Study.

Front Neurosci. 16: 784599Ullah A. Khan J. Waheed A. et al.

Parathyroid carcinoma: incidence, survival analysis, and management: a study from the seer database and insights into future therapeutic perspectives.

Cancers (Basel). 14https://doi.org/10.3390/cancers14061426Tao M. Luo S. Wang X. et al.

A Nomogram Predicting the Overall Survival and Cancer-Specific Survival in Patients with Parathyroid Cancer: A Retrospective Study.

Front Endocrinol. 13: 850457Dottorini L. Turati L. Mattei L. et al.

Definition and assessment of frailty in older patients: the surgical, anaesthesiological and oncological perspective.

Ecancermedicalscience. 14: 1105Hu Y. Bi Y. Cui M. et al.

The influence of surgical extent and parafibromin staining on the outcome of parathyroid carcinoma: 20-year experience from a single institute.

Endocr Pract. 25: 634-641Wang P. Xue S. Wang S. et al.

Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases.

Oncol Lett. 14: 7276-7282Hsu K.T. Sippel R.S. Chen H. et al.

Is central lymph node dissection necessary for parathyroid carcinoma?.

Surgery. 156 (): 1336-1341Silva-Figueroa A.M. Hess K.R. Williams M.D. et al.

Prognostic scoring system to risk stratify parathyroid carcinoma.

J Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2017.01.060Xue S. Chen H. Lv C. et al.

Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients.

Clin Endocrinol. https://doi.org/10.1111/cen.13055Machens A. Lorenz K. Dralle H.

Parathyroid hormone levels predict long-term outcome after operative management of parathyroid cancer.

Horm Metab Res. 49: 485-492Sun X.M. Pang F. Zhuang S.M. et al.

Tumor size rather than the thyroid invasion affects the prognosis of parathyroid carcinoma without lymph node or distant metastasis.

Eur Arch oto-rhino-laryngology. https://doi.org/10.1007/s00405-022-07403-wWei B. Zhao T. Shen H. et al.

Extended En bloc reoperation for recurrent or persistent parathyroid carcinoma: analysis of 31 cases in a single institute experience.

Ann Surg Oncol. 29: 1208-1215DeLellis R.A. Larsson C. Arnold A. et al.

Tumors of the parathyroid glands.

in: R Lloyd R. Osamura G. Kloppel J.R. In WHO classification of tumors of endocrine organs. IARC Press, : 145-159Villar-del-Moral J. Jimenez-Garcia A. Salvador-Egea P. et al.

Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study.

Surgery. 156: 1132-1144Hundahl S.A. Fleming I.D. Fremgen A.M. et al.

Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society.

Cancer. 86: 538-544Schulte K.M. Talat N. Miell J. et al.

Lymph node involvement and surgical approach in parathyroid cancer.

World J Surg. 34: 2611-2620Ferraro V. Sgaramella L.I. Di Meo G. et al.

Current concepts in parathyroid carcinoma: a single Centre experience.

BMC Endocr Disord. 19: 46Sandelin K. Tullgren O. Farnebo L.O.

Clinical Course of Metastatic Parathyroid Cancer.

World J Surg. 18: 594-599Tsai W.H. Zeng Y.H. Lee C.C. et al.

Mortality factors in recurrent parathyroid cancer: a pooled analysis.

J Bone Miner Metab. 40: 508-517

Understanding the genetic basis of parathyroid carcinoma.

Endocr Pathol. 25: 30-34Betea D. Potorac I. Beckers A.

Parathyroid carcinoma: Challenges in diagnosis and treatment.

Ann Endocrinol (Paris). 76: 169-177Cetani F. Banti C. Pardi E. et al.

CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.

Endocr Connect. 2: 186-195Ryhanen E.M. Leijon H. Metso S. et al.

A nationwide study on parathyroid carcinoma.

Acta Oncol. 56: 991-1003Guarnieri V. Battista C. Muscarella L.A. et al.

CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.

Cell Oncol (Dordr). 35: 411-422Wang O. Wang C. Nie M. et al.

Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.

PloS one. 7: e45567Witteveen J.E. Hamdy N.A. Dekkers O.M. et al.

Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.

Mod Pathol. 24: 688-697Hu Y. Cui M. Bi Y. et al.

Immunocyte density in parathyroid carcinoma is correlated with disease relapse.

J endocrinological Invest. https://doi.org/10.1007/s40618-020-01224-6Cetani F. Pardi E. Marcocci C.

Parathyroid Carcinoma.

Front Horm Res. 51: 63-76Perrier N.D. Arnold A. Costa-Guda J. et al.

Hereditary endocrine tumours: current state-of-the-art and research opportunities: new and future perspectives for parathyroid carcinoma.

Endocr Relat Cancer. 27: T53-T63Sawhney S. Vaish R. Jain S. et al.

Parathyroid carcinoma: a review.

Indian J Surg Oncol. 13: 133-142Christakis I. Silva A.M. Williams M.D. et al.

Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years.

Pract Radiat Oncol. 7: e463-e470Limberg J. Stefanova D. Ullmann T.M. et al.

The use and benefit of adjuvant radiotherapy in parathyroid carcinoma: a national cancer database analysis.

Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08825-8Rodrigo J.P. Hernandez-Prera J.C. Randolph G.W. et al.

Parathyroid cancer: An update.

Cancer Treat Rev. 86: 102012Machado N.N. Wilhelm S.M.

Parathyroid Cancer: A Review.

Cancers (Basel). 11https://doi.org/10.3390/cancers11111676Lerario A. Martin R. Oliveira A. et al.

Sorafenib treatment improves refractory hypercalcemia in a patient with metastatic parathyroid carcinoma: a case report. Endocr Soc Poster presented at: 2014; 2014; Chicago.

() ()Busaidy N. Cabanillas M.E. Dadu R. et al.

Metastatic parathyroid carcinoma and hypercalcemia responds to treatment with sorafenib. Endocr Soc Poster presented at: 2014; 2014; Chicago.

() ()Rozhinskaya L. Pigarova E. Sabanova E. et al.

Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases.

Endocrinol Diabetes Metab Case Rep. 2017https://doi.org/10.1530/EDM-16-0113Akirov A. Asa S.L. Larouche V. et al.

The clinicopathological spectrum of parathyroid carcinoma.

Front Endocrinol. 10: 731Anagnostou V. Bardelli A. Chan T.A. et al.

The status of tumor mutational burden and immunotherapy.

Nat Cancer. 3: 652-656Teng M.W. Ngiow S.F. Ribas A. et al.

Classifying cancers based on T-cell Infiltration and PD-L1.

Cancer Res. 75: 2139-2145Doroshow D.B. Bhalla S. Beasley M.B. et al.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors.

Nat Rev Clin Oncol. 18: 345-362Du X. Wang L. Shen B. et al.

Clinical significance of Pd-L1 expression in parathyroid cancer.

Acta Endocrinol (Buchar). 12: 383-386Silva-Figueroa A. Villalobos P. Williams M.D. et al.

Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages.

Surgery. https://doi.org/10.1016/j.surg.2018.06.013Spencer K.R. Wang J. Silk A.W. et al.

Biomarkers for immunotherapy: current developments and challenges.

Am Soc Clin Oncol Educ Book. 35: e493-e503Kang H. Pettinga D. Schubert A.D. et al.

Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy.

Oncologist. 24: 791-797Le D.T. Durham J.N. Smith K.N. et al.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science. 357: 409-413Park D. Airi R. Sherman M.

Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab.

BMJ case Rep. 13https://doi.org/10.1136/bcr-2020-235293Pandya C. Uzilov A.V. Bellizzi J. et al.

Genomic profiling reveals mutational landscape in parathyroid carcinomas.

JCI Insight. 2: e92061Kasaian K. Wiseman S.M. Thiessen N. et al.

Complete genomic landscape of a recurring sporadic parathyroid carcinoma.

J Pathol. 230: 249-260Clarke C.N. Katsonis P. Hsu T.K. et al.

Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways.

J Endocr Soc. 3: 544-559Kutahyalioglu M. Nguyen H.T. Kwatampora L. et al.

Genetic profiling as a clinical tool in advanced parathyroid carcinoma.

J Cancer Res Clin Oncol. 145: 1977-1986Waarts M.R. Stonestrom A.J. Park Y.C. et al.

Targeting mutations in cancer.

J Clin Invest. 132https://doi.org/10.1172/JCI154943Hsieh J.J. Chen D. Wang P.I. et al.

Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma.

Eur Urol. 71: 405-414Cui M. Hu Y. Bi Y. et al.

Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas.

Int J Cancer. 144: 525-532